IP Library Granted Patent US 8,491,917
Granted Patent B1
US 8,491,917 · App. 13/478,876 · Granted Jul 23, 2013

Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the head

Inventor: William J. Bender (Beverly Hills, CA)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,491,917
App. No.
13/478,876
Granted
Jul 23, 2013
Kind
B1
Abstract

A method for treating a patient with migraine headache in accordance with the present invention generally includes administering to the patient a therapeutically effective amount of a Botulinum toxin in a pharmaceutically safe form with the administration being on the trigeminal cervical system, for enabling axonal transport of the neurotoxin from distal to central sites. More specifically, the administration includes extramuscular injection of the neurotoxin over the aponeurotic fascia of the scalp for enabling the neurotoxin to diffuse into distal sensory nerves, in order to enable concentration over the occipital-parietal-frontal head region.

Claims (5)

1. A method for treating a human patient with migraine headache, said method comprising administering to the patient a therapeutically effective amount of diluted Botulinum toxin in a pharmaceutically safe form wherein said diluted Botulinum toxin is about 4-10 cc normal saline per 100 units of Botulinum toxin, said administration comprising extramuscular injection into one or more of the frontal, parietal and occipital aponeurotic fascia in the scalp.

2. The method according to claim 1 wherein the Botulinum toxin is Botulinum toxin A.

3. The method according to claim 1 wherein the Botulinum toxin is Botulinum toxin B.

4. The method according to claim 1 wherein the Botulinum toxin is an endopeptidase derived from Botulinum toxin.

5. The method according to claim 2 wherein the Botulinum toxin A is onabotulinumtoxinA.

Assignments (3)
SECURITY INTEREST Recorded Dec 22, 2023
From: MIOTOX, LLC
To: HCR COLLATERAL MANAGEMENT, LLC
Reel/Frame 065940/0196 →
SECURITY INTEREST Recorded Aug 14, 2019
From: MIOTOX, LLC
To: HCR COLLATERAL MANAGEMENT, LLC
Reel/Frame 050057/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2014
From: BINDER, WILLIAM J.
To: MIOTOX, LLC
Reel/Frame 032816/0988 →
Continuity (1)
Provisional Application 61609817 · Mar 12, 2012